ETON · Eton Pharmaceuticals, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 13, 2026TL;DR. Eton Pharmaceuticals posted record Q2 revenue of $37.6 million (+99% YoY) with adjusted EBITDA margin reaching 43%, raised 2026 revenue guidance to exceed $145 million (from >$120M) and adjusted EBITDA margin guidance to at least 35% (from >30%), completed the Hemangeol relaunch and patient conversion ahead of schedule, and added late-stage candidate ASN-001 plus U.S. rights to Impavido.
- + Adjusted EBITDA margin expanded to 43% from 16% a year ago
- + Raised full-year 2026 revenue guidance to exceed $145M from >$120M
- + Raised full-year adjusted EBITDA margin guidance to at least 35% from >30%
- − Adjusted gross margin declined to 73% from 75% due to negative-margin ex-U.S. Increlex sales
- − $3M ASN-001 upfront licensing payment will be expensed as R&D in Q3 2026, pressuring near-term R&D spend
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ETON
this stock
Eton Pharmaceuticals, Inc.
|
$1.63B | +237.6% | +104.9% | — | 4.7% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.31B | +17.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$44.03B | -8.9% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$43.22B | +18.8% | +4.3% | 60.8 | 3.2% |
|
HLN
Haleon plc
|
$40.41B | -9.1% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ETON | -4.7% | +39.9% | +155.7% | -5.6% | +237.6% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -3.6% | +41.7% | +137.9% | -5.2% | +225.5% |